Metagenomi
Cell & Gene Therapy
$345.1Mtotal raised · 5 rounds on record
$95.8Mlatest round · Venture round · Dec 2022 · 3 yr ago
2backers · RA Capital Management, Sozo Ventures
203team · US Form 5500 (plan participants) · Dec 2024
Overview
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients.
Funding and backers
Total raised
$345.1M
5 rounds on record
Latest round
$95.8M
Venture round · Dec 2022 · 3 yr ago
Team
203
US Form 5500 (plan participants) · Dec 2024
Backers
2
RA Capital Management, Sozo Ventures
The money's age
Long since its last round
46 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 11, 2023
Board appointment Santhosh Palani, Director · SEC Form D
Dec 20, 2022
Raised a round Venture round $95.8M · SEC Form D
Feb 7, 2022
Board appointment Santosh Palani, Director · SEC Form D
Jan 21, 2022
Raised a round Venture round $175.4M · SEC Form D
Mar 29, 2021
Board appointment Andrew Levin, Director · SEC Form D
Mar 15, 2021
Raised a round Venture round $10M · SEC Form D
Nov 25, 2020
Board appointment Juergen Eckhardt, Director · SEC Form D
Nov 10, 2020
Raised a round Venture round $37.5M · SEC Form D
Aug 2, 2019
Raised a round Venture round $26.4M · SEC Form D
2018
Founded
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Dec 2022 | $95.8M | — | SEC Form D |
| Venture round | Jan 2022 | $175.4M | — | SEC Form D |
| Venture round | Mar 2021 | $10M | — | SEC Form D |
| Venture round | Nov 2020 | $37.5M | — | SEC Form D |
| Venture round | Aug 2019 | $26.4M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Metagenomi Technologies, LLC | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Brian ThomasExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome…
Vyriad engineers targeted virus platforms that bring durable in vivo gene therapies, genome editing, and oncolytic virotherapies to…
About Us We build the medicines we wish existed CPTx is a genetic medicines company redefining how we treat disease using immune-silent…
Developing scalable in-vivo genomic medicine for blood disorders.
Signadori Bio is a preclinical stage biopharmaceutical company developing a next generation in vivo monocyte immunotherapy to treat solid…
Reforgene is a Chinese biotechnology company developing cell and gene therapies. Its research covers ex vivo and in vivo gene editing, gene…
Visa sponsorship
1 ▼ 88%
H-1B filings in 12 months
1
Green card filings
$150k
Median offered salary
Who they sponsor
Other biological scientists
1
In the register as Metagenomi, Inc., Emeryville, CA (+1 more)
Other sponsors in the same field
Vertex Pharmaceuticals 
Genscript 
Kite Pharma 
Alnylam
Alert me
US Department of Labor · latest filing Apr 9, 2026 · Visa details by country
Financials
Total raised
$345.1M
Latest round
Venture - Series Unknown
Funding rounds
5
People
Brian Thomas
Executive Officer, Director
Andrew Farquharson
Director
Jak Knowles
Director
Sebastian Bernales
Director
Juergen Eckhardt
Director
Andrew Levin
Director
Risa Stack
Director
Willard Dere
Director
Santosh Palani
Director
Santhosh Palani
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Sozo VenturesVia a fund
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Metagenomi updates hemophilia A gene editing program
Detailed price information for Metagenomi Therapeutics Inc (MGX-Q) from The Globe and Mail including charting and trades.
Read more
Report
Report
Metagenomi (MGX) Presents Latest in Gene Editing Technologies
Metagenomi, Inc. (NASDAQ:MGX) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 14, Metagenomi, Inc. (NASDAQ:MGX) announced that it is presenting three abstracts at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, hel
Read more
Report
Metagenomi On Track For IND Submission For MGX-001 In 2026
(RTTNews) - Metagenomi, Inc. (MGX), a precision genetic medicines company, on Thursday announced significant progress in its therapeutic development programs, particularly its MGX-001 gene editing candidate for Hemophilia A.
Read more
Report
Expert Outlook: Metagenomi Through The Eyes Of 4 Analysts
In the latest quarter, 4 analysts provided ratings for Metagenomi (NASDAQ:MGX), showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and ...
Read more
Report
Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Moderna-backed Metagenomi targets up to $638 million valuation for US IPO
At the top end of the proposed range, the IPO would fetch $106.25 million for the Emeryville, California-based startup. Metagenomi, one of a string of companies from the healthcare sector that have sought listings recently, is developing therapies for gen
Read more
Report
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Chicago
United States
HQ
One Design Company
Emeryville
United States
Regional office
5959 Horton St, Floor 7
5959 Horton St, Floor 7, Emeryville, California 94608